HUTCHMED and Citigroup to Host Nov. 5 Webcast on Phase III Savolitinib Data in MET-Driven NSCLC

HUTCHMED (China) Limited will co-host an expert webcast with Citigroup Global Markets Asia Limited on November 5, 2026, to discuss recent Phase III savolitinib data in MET-driven non-small cell lung cancer presented at the European Society for Medical Oncology Congress 2026, Stock Titan reported. The virtual event will take place at 4:30 pm HKT.

HUTCHMED's Savolitinib Webcast Details

The discussion will be led by Professor Yi-Long Wu, principal investigator of the SANOVO study, who will share insights on the latest clinical data and treatment strategies for MET-driven NSCLC. Dr Weiguo Su, Chief Executive Officer presently on leave of absence and Chief Scientific Officer of HUTCHMED, will also join the panel to discuss the development progress to date and global regulatory outlook of savolitinib in light of data from both the SANOVO study in China and the SAFFRON global study. The event will be moderated by Mr Yingqi Peng, Asia Healthcare Research Analyst from Citigroup.

The webcast will be conducted in Chinese (Putonghua) with simultaneous English interpretation. Event and registration details will be available at www.hutch-med.com/event.

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It is marketed in China under the brand name ORPATHYS for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

SANOVO and SAFFRON Trial Background

SANOVO is a blinded, randomized, controlled Phase III trial in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression in China conducted by HUTCHMED. A total of 326 treatment-naïve patients were randomized in a 1:1 ratio to receive TAGRISSO 80 mg once daily plus either savolitinib or placebo at 300/200 mg twice daily.

SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of savolitinib added to TAGRISSO versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO. The trial enrolled patients in 230 centers across 29 countries.

Earlier HUTCHMED Milestones

In September 2026, AstraZeneca submitted an FDA NDA for ORPATHYS plus TAGRISSO to treat MET-driven EGFR-mutated lung cancer after EGFR-TKI progression, FinancialContent Business Page reported. HUTCHMED also highlighted that new clinical data from two Phase III studies, including results from the SAFFRON and SANOVO studies, would be presented at ESMO Congress 2026 in Madrid, according to FinancialContent Business Page.

ESMO 2026 Peer Data

At ESMO, AstraZeneca showcased its cancer pipeline, with four of 12 presidential sessions featuring its medicines, STAT reported. Hansoh Pharma presented Phase 1 results for HS-20122 showing a 61.3% response rate in EGFR-mutant lung cancer after TKI failure, The future of trading reported. GenFleet Therapeutics presented initial Phase Ia results for oral pan-RAS inhibitor GFH276 showing a 41.1% response rate in early-stage pancreatic cancer, The future of trading reported.

Next Steps for HUTCHMED (China) Limited

The webcast will take place on November 5, 2026, at 4:30 pm HKT. The event will be conducted in Chinese with simultaneous English interpretation.